Alternatively, the influence of telomere length was evaluated within intratumor and peritumor areas. Using the median telomere length as the cut‐off (tumor cell median = 11.8, IQR 3.3–22.2; CAF median = 42.9, IQR 26.8–61.4), patients were also classified into shorter and longer groups. Kaplan–Meier analysis demonstrated that the median OS time was 43.2 and 56.4 months for patients with shorter and longer telomeres in tumor cells, respectively (p < 0.0001, supplementary material, Figure S4A). The median TTR was 40.8 and 51.3 months for patients with shorter and longer telomeres in tumor cells, respectively (p = 0.007, supplementary material, Figure S4B). Likewise, we also found that patients with shorter telomeres in CAFs had a significantly poorer OS (44.7 versus 58.3 months, p = 0.008, supplementary material, Figure S4C) and TTR (42.2 versus 50.4 months, p = 0.048, supplementary material, Figure S4D; log‐rank test for each comparison). However, telomere variation in peritumoral liver cells and NTFs showed no prognostic significance.